{"analyses":[{"ciLowerLimit":"0.657","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.711","estimateComment":"Odds ratio and 95% CIs were estimated by a stratified analysis using the Cochran-Mantel-Haenszel method.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Odds Ratio (OR)","paramValue":"1.060"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.3","upperLimit":"23.8","value":"18.1"},{"groupId":"OG001","lowerLimit":"14.0","upperLimit":"24.6","value":"18.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"The percentage of participants with achievement of MRD\\[-\\] at 12 months (± 4 weeks) from randomization, as assessed by next generation sequencing method at a 10\\^-5 threshold. MRD negativity results from BM samples obtained at 8 to 13 months from randomization and prior to new anti-myeloma therapy or disease progression were considered in the calculation. The 95% CIs for percentages were estimated using the Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 up to 12 months (cycle = 28 days)","title":"Percentage of Participants With Minimal Residual Disease Negativity (MRD[-]) by IRC Per IMWG-URC at 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}